An Anti-CD6 Monoclonal Antibody for the Treatment of Autoimmune Diseases

• Explore how selective immune modulation can control disease-driving responses while preserving protective immunity to improve therapeutic safety and long-term patient outcomes
• Assess strategies to induce immune tolerance while maintaining anti-tumor immunity, expanding the therapeutic potential of ASIT approaches across diseases
• Analyzing the distinctions in the molecular interactions between anti-CD6 and CD4+ versus CD8+ T-cells

Speakers:

David Fox

Professor Rheumatology, Internal Medicine

University of Michigan, Immune Tolerance Network, Abcon